transmembrane p24 trafficking protein 11, pseudogeneGenealiases: p24a1 · p24alpha1
Q-omics provides the consensus-scored TMED11P profile across patient tissues and cancer cell-line models. TMED11P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, TMED11P is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, TMED11P RNA expression shows 9,550 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KICH, KIRC, and PDAC as cancer lineages where TMED11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMED11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMED11P survival associations across molecular data types. TMED11P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMED11P RNA expression–survival associations across cancer types. High TMED11P expression shows unfavorable associations in KICH, ACC, LIHC, GBM and CHOL, but favorable associations in THYM. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for TMED11P RNA expression.
This table summarizes TMED11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TMED11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMED11P shows lower tumor expression in KIRC, THCA, BLCA and KICH and higher tumor expression in PRAD and LUAD. The KIRC box plot shows higher TMED11P RNA expression in normal versus tumor tissue (log2 FC = −0.097, t-test p < 0.001).
This table shows molecular features associated with TMED11P in patient tissues and cancer cell lines. In patient samples, TMED11P shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
